Effect of frequent dosing of an oral proton pump inhibitor on intragastric pH

Pais, Shireen; Nathwani, Rahul A.; Dhar, Vasudha; Nowain, Arash; Laine, Loren

doi:10.1111/j.1365-2036.2006.02933.x

Cited by 8 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors conclude that oral dosing of lansoprazole at the stated doses could not reliably maintain the gastric pH at 6 or above. 17 Although the level of acid control is not as good as that achieved with the 80 mg bolus followed by 8 mg/hour, it may be useful if there is going to be a delay in the patient reaching hospital.…”

Section: Emergency Treatmentmentioning

confidence: 97%

Reducing gastrointestinal tract bleeding in family practice

Schneider

2008

South African Family Practice

View full text Add to dashboard Cite

Upper gastrointestinal bleeding occurs commonly. Fortunately, severe life-threatening bleeding is less common, but can be catastrophic, particularly in the elderly patient with co-morbidity such as cardiac or respiratory disease. In order to reduce the risk of bleeding, it is necessary to examine the causes of bleeding and, where possible, modify the risk factors. This review will focus on the prevention of non-variceal upper gastrointestinal bleeding. This article has been peer reviewed. Full text available at www.safpj.co.za SA Fam Pract 2008;50(1):13-17

show abstract

Section: Emergency Treatmentmentioning

confidence: 97%

Reducing gastrointestinal tract bleeding in family practice

Schneider

2008

South African Family Practice

View full text Add to dashboard Cite

show abstract

“…Although this has not been tested in clinical outcomes studies, a US study of intragastric pH found that an initial oral dose of 120 mg lansoprazole followed by four oral doses of 30 mg every 3 hours did not reliably sustain pH at the desired level of 6 [33]. • The combination of uncoated omeprazole with sodium bicarbonate may be applicable for delivery endoscopically at the time of index endoscopy but has not been studied.…”

Section: Emerging Therapiesmentioning

confidence: 99%

Pharmacologic treatment of peptic ulcer bleeding

Leontiadis

Howden²

2007

Curr Treat Options Gastro

View full text Add to dashboard Cite

Over the last 3 decades, there has been extensive clinical research on the pharmacologic treatment of peptic ulcer bleeding. A critical review of randomized controlled trials and meta-analyses reveals insufficient evidence to recommend histamine-2 receptor antagonists (H(2)RAs), somatostatin, octreotide, or tranexamic acid in the routine management of patients with peptic ulcer bleeding. In contrast, there is good-quality evidence for recommending proton-pump inhibitor (PPI) treatment for patients with peptic ulcer bleeding. PPI treatment, compared with an H(2)RA or placebo, reduces rebleeding and the need for surgical intervention and, in patients with high-risk endoscopic stigmata, also reduces all-cause mortality. Patients with ulcers that demonstrate only low-risk endoscopic stigmata (clean base or flat pigmented spot) can be treated with an oral PPI at double the standard clinical dose. Patients with ulcers that demonstrate high-risk endoscopic stigmata (spurting, oozing, or nonbleeding visible vessel) should receive high-dose intravenous PPI treatment following appropriate endoscopic hemostatic treatment. The currently recommended dose is an initial intravenous bolus equivalent to 80 mg of omeprazole followed by an intravenous infusion equivalent to 8.0 mg/h of omeprazole for up to 72 hours. A switch to high-dose oral PPI treatment may be appropriate before completion of a 72-hour treatment period in some patients whose clinical status stabilizes early. Once the initial bleeding episode has been dealt with, patients will require standard pharmacologic treatment to heal the ulcer and prevent recurrence.

show abstract

Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve

Niioka

Uno

Yasui‐Furukori

et al. 2006

Eur J Clin Pharmacol

View full text Add to dashboard Cite

The present study demonstrated that the AUC of rabeprazole can be estimated by the simple formula using two-point concentrations. This formula can be more accurate for the prediction of AUC estimation than that reflected by CYP2C19 genotypes without any determination, even if there are significant differences for the CYP2C19 genotypes. Therefore, this prediction formula might be useful to evaluate whether CYP2C19 genotypes really reflects the curative effect of rabeprazole.

show abstract

Effect of frequent dosing of an oral proton pump inhibitor on intragastric pH

Abstract: SUMMARY BackgroundTreatment with a continuous i.v. proton pump inhibitor is presumed to promote clot formation and stability by sustaining intragastric pH ‡ 6.

Cited by 8 publications

References 26 publications

Reducing gastrointestinal tract bleeding in family practice

Reducing gastrointestinal tract bleeding in family practice

Pharmacologic treatment of peptic ulcer bleeding

Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve

Contact Info

Product

Resources

About